Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Ab Cellera Biologics Inc. Transaction History
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main
- $94.9 Billion
- Q3 2024
A detailed history of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main holds 2,300 shares of ABCL stock, worth $6,785. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,300
Previous 2,300
-0.0%
Holding current value
$6,785
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ABCL
# of Institutions
154Shares Held
109MCall Options Held
153KPut Options Held
194K-
Baker Bros. Advisors LP New York, NY27.5MShares$81.2 Million0.76% of portfolio
-
Baillie Gifford & CO12.9MShares$38 Million0.03% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$31.3 Million0.03% of portfolio
-
Prosight Management, LP Dallas, TX9.08MShares$26.8 Million6.31% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.59MShares$13.5 Million0.0% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $841M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...